For more information contact:
John L. Tonkinson, Ph.D., Chief Business Development Officer
Main: +1-760-804-3886 | Mobile: +1-860-977-4012
Elizabeth Ward, Product Manager
Main: +1-858-565-4227 x156
April 9, 2019
DCN Diagnostics to Distribute nanoComposix Gold NanoShell Particles
New deal expands labelling reagent options available through DCNovations
DCN Dx, a Carlsbad, California-based developer and manufacturer of rapid point-of-care diagnostic tests, today entered into a distribution agreement with nanoComposix, a San Diego, California-based manufacturer of precisely engineered and highly characterized nanoparticles.
The agreement allows DCN Dx to distribute nanoComposix carboxyl gold nanospheres and gold nanoshells for use in lateral flow immunoassays under its DCNovations product line.
DCN Dx’s DCNovations product line enables customers to develop and manufacture their own lateral flow assays. The gold nanosphere and gold nanoshell products will expand the labeling reagents already offered under the DCNovations brand including colloidal gold and cellulose nanobeads.
“This addition provides our customers with another excellent labeling system for assays they are developing and allows DCN to offer customers of its contract development services access to yet another innovative solution to their assay development needs,” said DCN Dx President Brendan O’Farrell. “We are delighted to offer nanoparticles from nanoComposix.”
“Gold nanoshells have unique optical properties that can dramatically improve diagnostic test performance. We are excited to be partnering with DCN to provide their customers with robust and reliable solutions for increasing the sensitivity and reproducibility of lateral flow assays,” said nanoComposix President Dr. Steven Oldenburg.
DCN Dx provides complete design, development, and manufacturing services for rapid diagnostic assays and associated disposable devices at its ISO 9001:2015 and EN 13485:2016 certified facility in Carlsbad. Since its founding more than 12 years ago, DCN Dx has been committed to furthering the rapid diagnostic test market through the continued evolution of technologies and applications related to lateral flow assays.
For over 15 years, nanoComposix has provided development, fabrication, processing, and scale-up expertise to accelerate the commercialization of nanomaterials in a wide range of applications that include biodiagnostics, therapeutics, drug delivery, and specialized coatings. NanoComposix manufactures nanomaterials for medical devices, clinical trials, and therapeutics under a cGMP and EN 13485:2016 compliant quality management system.